Compare Bristol-Myers Squibb Co (BMY) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Funko Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.83 (market cap $116.30B), while Funko Inc trades at $5.82 (market cap $310.19M). The key difference: Bristol-Myers Squibb Co is far larger — about 374.9× Funko Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| BMY | FNKO | |
|---|---|---|
Market Cap | $116.30B | $310.19M |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $5.88 |
52-Week Low | $42.60 | $2.46 |
Enterprise Value | $152.24B | $555.22M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
FNKO trades at $5.69, up 1.97% with a bullish technical signal. Recent earnings beat expectations, yet the company reported a net loss of $67.36M in 2025. Revenue declined to $908.21M, but Q1 2026 showed improvement. Analyst consensus is mixed with 42.86% buy ratings. Cash flow trends are stabilizing, though negative profitability and high debt remain concerns.
Outlook hinges on execution of new product launches and cost management. Opportunities include brand strength and collectibles demand, but risks involve sustained losses, competitive pressure, and leverage. The stock presents a speculative growth play with significant turnaround requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
